Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Oligometastatic Prostate Cancer

Trial Status: active

This phase I trial studies the feasibility of combining stereotactic body radiation therapy (SBRT) and 177Lu-prostate-specific membrane antigen (PSMA)-617 in patients with prostate cancer that has spread to a limited number of sites (oligometastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. 177Lu-PSMA-617 specifically binds prostate cancer cells and may improve the effect of SBRT.